Eikon Therapeutics (EIKN) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$1.63

Estimate

-$1.46

Surprise

-11.5%

Score today

5.6/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Eikon Therapeutics (EIKN) reported a wider loss than forecast — diluted EPS of -$1.63 against the -$1.46 estimate (a 11.5% shortfall).

• Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $4 — benzinga, 2026-08-14
• Eikon Therapeutics Q2 EPS $(1.63) Misses $(1.54) Estimate — benzinga, 2026-08-13
• Eikon Therapeutics Announces Selection Of Dose Of 0.60 mg/m2 To Be Employed In Future For All Patients Randomized To Rec — benzinga, 2026-08-11

TrendMatrix currently rates EIKN Sell at 5.6/10; no pre/post engine snapshot brackets this report.

0 of the last 3 quarters beat the estimate; this quarter's -11.5% surprise compares with a -53.7% four-quarter average. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$11.39

Price target

$21.40

Stop

$10.59

Upside to target

+87.9%

Reward-to-risk

5.9:1

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$616.9M

P/E (fwd)

-1.8

52-week range

$7.90–$17.40

Off 52-week high

34.5%

RSI (14)

66

Volume vs avg

1.15×

Score today

5.6/10